Shots:
- GSK has entered into a global collaboration & license agreement with Halozyme to develop & commercialize SC formulation of multiple oncology targets, incl. ADCs, as well as an option for additional future drug targets
- As per the deal, GSK will license Enhanze drug delivery tech from Halozyme in exchange of upfront payment, as well as milestone payments, plus royalties, with the first clinical trial anticipated to initiate in 2026
- Enhanze is a rHuPH20-based drug delivery technology that allows rapid SC administration of injected therapies & fluids to improve patient experience & reduce treatment burden
Ref: Prnewswire | Image: GSK & Halozyme | Press Release
Related News: Siran Bio Inks ~$1B Licensing Deal with GSK for SA030
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
